Triangle Insights Taps Veteran Erin Solano to Navigate Biotech Maze

DURHAM, N.C. – March 10, 2026 – In a strategic move signaling a deeper investment in top-tier expertise, Triangle Insights Group by Valeris has appointed Erin Solano, a veteran life sciences executive, as its newest Partner. The appointment comes as consulting firms face a fierce battle for talent, seeking leaders capable of guiding pharmaceutical and biotech clients through an increasingly convoluted global commercialization landscape.

Solano, who previously served as a Managing Director at Syneos Health Consulting, brings a formidable track record in market access, pricing strategy, and global product launches. Her arrival at the Durham-based strategy firm is more than just a new hire; it represents a calculated reinforcement of Triangle's capabilities at a time when the life sciences industry is grappling with unprecedented challenges and opportunities.

The High Stakes of a Talent War

The life sciences consulting market is booming, with projections estimating a compound annual growth rate of over 9% to reach nearly $85 billion by 2034. This rapid expansion is fueling an intense 'war for talent,' where specialized firms are competing to attract and retain leaders with the specific, nuanced expertise required by the industry.

Solano's profile fits the bill perfectly. With an MBA from Yale and extensive experience spanning large pharmaceutical giants, nimble biotech startups, and medical device manufacturers, she embodies the multi-faceted leadership that firms are desperate to secure. Her work has guided clients from their first product launch to managing established global portfolios, giving her a unique ground-level and C-suite perspective. This hire underscores a critical trend: in today's market, the quality of a consulting firm's intellectual capital—embodied by its leaders—is its primary competitive advantage.

"We are thrilled to have a proven leader like Erin join our team," said Megan Thomas, General Manager of Triangle. "Her vast experience in life sciences consulting will help Triangle meet our short- and long-term goals. We look forward to the role Erin will play in accelerating further growth of the company."

Mastering the Commercialization Labyrinth

Solano's expertise is particularly relevant to the most pressing challenges facing drug and device developers today. The path from laboratory to patient has never been more complex, fraught with regulatory hurdles, pricing pressures, and market access barriers.

One of the most significant challenges is navigating drug pricing and reimbursement. In the United States, the Inflation Reduction Act (IRA) has empowered Medicare to negotiate drug prices for the first time, a seismic shift whose full impact will begin to be felt in 2026. This, combined with persistent pressure from payers to demonstrate clear value, requires a sophisticated approach to pricing and health economics—a core area of Solano's experience.

Furthermore, the rise of biosimilars presents both an opportunity for cost savings and a complex competitive dynamic. While biosimilar approvals are increasing, market uptake has been hampered by a web of rebates and formulary decisions. Experts have even warned of a potential "biosimilar void," where a lack of development for many off-patent biologics could represent a massive missed opportunity for healthcare savings. Solano's background in this area will be crucial for clients seeking to launch or compete against these products.

Her experience is not limited to traditional pharmaceuticals. With a background that includes launches in advanced therapy areas like cell and gene therapy, oncology, and rare diseases, Solano is equipped to handle the unique commercialization hurdles associated with these high-cost, high-impact innovations. These therapies often require novel payment models, such as value-based contracting, and intricate supply chain logistics, demanding the kind of specialized strategic guidance she provides.

A Critical Piece in Valeris's Integrated Vision

Solano's appointment is not just a win for Triangle Insights Group but a significant step in the broader strategic vision of its parent company, Valeris. Formed in 2025 through the landmark merger of Mercalis and PharmaCord, Valeris was created to be a fully integrated, end-to-end life sciences commercialization partner.

The company's model is built on the premise that siloed functions—from high-level market strategy to on-the-ground patient support services—are no longer sufficient. Valeris aims to provide a seamless solution that spans the entire healthcare value chain, combining strategic insights, patient services, and technology.

Within this ecosystem, Triangle Insights Group serves as the crucial "Insights and Data" engine, providing the foundational strategic guidance that informs the entire commercialization process. By bringing in a leader of Solano's caliber, Valeris is strengthening the very core of its integrated offering. Her expertise in market access and commercial strategy directly feeds into Valeris's ability to help its more than 500 biopharmaceutical partners successfully get their products to market and ensure patients can access and adhere to them.

This move demonstrates Valeris’s commitment to building a powerhouse of expertise that can address client needs from initial portfolio strategy to post-launch patient engagement, reinforcing the synergy promised by the 2025 merger.

Bolstering a Specialized Powerhouse

Since its founding in 2013, Triangle Insights Group has carved out a reputation as a premier strategy firm by focusing exclusively on the life sciences. Its deep knowledge in key therapeutic areas like oncology and CNS, combined with functional expertise in pricing and new product planning, has made it a go-to partner for industry leaders.

Solano's global experience—spanning major and minor markets in Europe, Asia, Latin America, and the Middle East—adds another layer of depth to the firm's capabilities. As pharmaceutical and biotech companies increasingly think globally from day one, having leadership that has navigated diverse international regulatory and reimbursement systems is invaluable.

Her appointment is a clear signal that Triangle, backed by the resources of Valeris, is not just consolidating its current strengths but actively preparing for the future. By investing in leadership with proven success in the most innovative and challenging sectors of the industry, the firm is positioning itself to lead its clients through the next wave of therapeutic breakthroughs and market transformations. This strategic enhancement of its leadership team ensures the firm is well-equipped to guide clients through the next frontier of healthcare innovation.